We observed a significantly higher frequency of TERTp mutation, EGFR amplification, and EGFR rearrangement (including mutations and amplification) in primary glioblastoma samples compared with recurrent cases from subsequent resections (77.0% vs. 56.4%, 47.9% vs. 20.5%, and 68% vs. 25.6%, respectively. Here, EGFR is linked to glioblastoma.